Pathogenesis and recent therapeutic trends in Stevens-Johnson syndrome and toxic epidermal necrolysis
- 30 September 2006
- journal article
- review article
- Published by Elsevier
- Vol. 97 (3) , 272-281
- https://doi.org/10.1016/s1081-1206(10)60789-2
Abstract
No abstract availableKeywords
This publication has 62 references indexed in Scilit:
- Novel Treatments for Drug-Induced Toxic Epidermal Necrolysis (Lyell’s Syndrome)International Archives of Allergy and Immunology, 2005
- Prospective, noncomparative open study from Kuwait of the role of intravenous immunoglobulin in the treatment of toxic epidermal necrolysisInternational Journal of Dermatology, 2004
- Toxic Epidermal Necrolysis: Does Immunoglobulin Make a Difference?Journal of Burn Care & Rehabilitation, 2004
- Improvement of toxic epidermal necrolysis after the early administration of a single high dose of intravenous immunoglobulinAnnals of Allergy, Asthma & Immunology, 2003
- Intracellular Localization of Keratinocyte Fas Ligand Explains Lack of Cytolytic Activity under Physiological ConditionsJournal of Biological Chemistry, 2003
- Nitric Oxide Synthase in Toxic Epidermal Necrolysis and Stevens–Johnson SyndromeJournal of Investigative Dermatology, 2000
- Would Cyclosporin A Be Beneficial to Mitigate Drug-Induced Toxic Epidermal Necrolysis?Dermatology, 1999
- HLA-restricted, processing- and metabolism-independent pathway of drug recognition by human alpha beta T lymphocytes.Journal of Clinical Investigation, 1998
- Severe Adverse Cutaneous Reactions to DrugsNew England Journal of Medicine, 1994
- Phenytoin hypersensitivity reaction presenting with toxic epidermal necrolysis and severe hepatitis: Report of a patient treated with corticosteroid “pulse therapy”Journal of the American Academy of Dermatology, 1985